Together, these studies suggest that MAO-B inhibitors administered in addition to background therapy (i.e. acetylcholinesterase inhibitors, memantine) in patients with moderate AD may not add to the cognitive benefit. The gene discussed is MAOB; the disease is Alzheimer disease.